Literature DB >> 20811368

Potential remains for PPAR-targeted drugs.

Dan Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20811368     DOI： 10.1038/nrd3271

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

Authors:  Robert R Henry; A Michael Lincoff; Sunder Mudaliar; Michael Rabbia; Cathy Chognot; Matthias Herz
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

2.  Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

Authors:  Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman
Journal:  Nature       Date:  2010-07-22       Impact factor: 49.962
  2 in total
  16 in total

Review 1.  Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

Authors:  Sachin K Majumdar; Silvio E Inzucchi
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

2.  Amorfrutins are potent antidiabetic dietary natural products.

Authors:  Christopher Weidner; Jens C de Groot; Aman Prasad; Anja Freiwald; Claudia Quedenau; Magdalena Kliem; Annabell Witzke; Vitam Kodelja; Chung-Ting Han; Sascha Giegold; Matthias Baumann; Bert Klebl; Karsten Siems; Lutz Müller-Kuhrt; Annette Schürmann; Rita Schüler; Andreas F H Pfeiffer; Frank C Schroeder; Konrad Büssow; Sascha Sauer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

3.  Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.

Authors:  Laura Guasch; Esther Sala; Cristina Valls; Mayte Blay; Miquel Mulero; Lluís Arola; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  J Comput Aided Mol Des       Date:  2011-06-21       Impact factor: 3.686

Review 4.  The Structure Basis of Phytochemicals as Metabolic Signals for Combating Obesity.

Authors:  Xiaoping Li; Liufeng Zheng; Bing Zhang; Ze-Yuan Deng; Ting Luo
Journal:  Front Nutr       Date:  2022-06-13

5.  Simultaneous non-negative matrix factorization for multiple large scale gene expression datasets in toxicology.

Authors:  Clare M Lee; Manikhandan A V Mudaliar; D R Haggart; C Roland Wolf; Gino Miele; J Keith Vass; Desmond J Higham; Daniel Crowther
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Pseudoginsenoside F11, a Novel Partial PPAR γ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes.

Authors:  Guoyu Wu; Junyang Yi; Ling Liu; Pengcheng Wang; Zhijie Zhang; Zhen Li
Journal:  PPAR Res       Date:  2013-12-18       Impact factor: 4.964

7.  Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.

Authors:  Sabina Yasmin; Fabio Capone; Antonio Laghezza; Fabrizio Dal Piaz; Fulvio Loiodice; Viswanathan Vijayan; Velmurugan Devadasan; Susanta K Mondal; Özlem Atlı; Merve Baysal; Ashok K Pattnaik; Venkatesan Jayaprakash; Antonio Lavecchia
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

8.  PPARD is an Inhibitor of Cartilage Growth in External Ears.

Authors:  Zhen Zhang; Yanyu Duan; Zhongping Wu; Hui Zhang; Jun Ren; Lusheng Huang
Journal:  Int J Biol Sci       Date:  2017-05-16       Impact factor: 6.580

9.  Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation.

Authors:  Laura Guasch; Esther Sala; Anna Castell-Auví; Lidia Cedó; Klaus R Liedl; Gerhard Wolber; Markus Muehlbacher; Miquel Mulero; Montserrat Pinent; Anna Ardévol; Cristina Valls; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.

Authors:  Sin Gon Kim; Doo Man Kim; Jeong-Taek Woo; Hak Chul Jang; Choon Hee Chung; Kyung Soo Ko; Jeong Hyun Park; Yong Soo Park; Sang Jin Kim; Dong Seop Choi
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.